| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10072019 | American Journal of Ophthalmology | 2005 | 6 Pages |
Abstract
In superficial opacities that are caused by macular corneal dystrophy, PTK can increase BCVA moderately for a limited period of time. Despite possible complications, primary PK still appears to be the definite therapeutic option for patients with macular corneal dystrophy.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Andrea MD, Achim PhD, Berthold (FEBO),